PDFファイル - 医薬品医療機器総合機構
Contents
1. ug mL Buchthal and Lennox Buchthal3 15 25 Finn and Olanow 10 20 6 14 Jusko 10 20 Kutt 10 20 Buchthal and Svensmark 10 20 Sohn and Ferrendelli9 10 25 Penry and Newmark 9 10 20 1 20 2 0 7g mL 202 8 1 3 71702. IH 1 2 B F 3 4 1 1 2 15 30C
3. 85 95 87 942 5 70 802 5 5 HPPH 9 HPPH 902 2 5 9 10 20z g mL9 9 10 6 14 g g mL 9
4. Henderson 2 CEDIA Cloned Enzyme Donor Immunoassay I DNA EIA CEDIA DNA 2 8 PA 8 ED 8 EA ED EEA
5. ED J EA ED D 2 II
6. 4 5 4 1 1 2 8C 2 2 EA 18mL x1 EA 18mL x1 I ED 18mL x1 ED 18mL x1 1 Fowler A and Zabin 1 Amino acid sequence of galactosidase J Biol Chem 253 5521 5525 1978 2 Henderson D R Friedman S B Harris J D Manning W B Zoccoli M A CEDIATM a new homogeneous immunoassay system Chn
7. 6 1 EA 8 EA 3 08 0 15mg 18mL EA 1 12 0 45mg 18mL ED 8 ED 0 45 0 09 g 18mL D 29 5 2 95mg 18mL ED 2 N 87 8mg 18mL
8. 3 9 3 2 8 1 1 bil 1 Fowler B 2
9. 5 TDM II 75mLx 1 50mLx 1 13 5 ma Microgenics Corporation 46360 Fremont Boulevard Fremont CA 94538
10. 0 7 40 0 g mL N 118 r 0996 y 10lx 0 25 CEDIA N 93 r 0997 1 07x 048 1 1 HIV HBV HCV 2 2 1
11. 1 1 EA R1 EA 2 ED R2 ED EA ED 8 2 8C 60 2 EA 37C 21uL 89uL 5 ED 37C 89gL 237 308 660nm 570nm TDM II EA EA ED ED 1 10 20 gw g mL9 9 10 6 14 g mL
12. 2 3 4 ED EA ED 3 0 1 1 121C 20 2 0 1 3
13. 0 1 03 02 10 11 0 1 909 01 04 1 5 00 47 04 1 1 2 2 00 2 6 0 0 0 0 p 0 2 16 00 00 03 5 p 5 5 7 07 00 03 00 01 3 1 TDM I 2 x 2
14. 24 4 2 8 20C 3 4 2 1 66mg dL 1 000mg dL 1 200mg qdL 12 4g dL 2 3 4 5 5 18 5 5 00 00
15. Chem 32 9 1637 1641 1986 3 Buchthal F Lennox Buchthal M A DiphenyIhydantom Relation of anticonvulsant effect to concentration in serum in Woodbury D M Penry J K Schmidt K P eds Antiepileptic Drugs Raven Press New York pp 193 209 1972 4 Finn A L Olanow C W Phenytoin Therapeutic use and serum concentration monitoring in Taylor W J Fin A L eds Individualizing Drug Therapy Practical Application of Drug Monitoring Vol 2 Gross Townsend Frank Inc New York pp 63 85 1981 5 Porter R J Layzer R B Plasma albumin concentration and diphenylhydantoin binding in man Arch Neurol 32 298 303 1975 6 Jusko W J Bioavailability and disposition kinetics of phenytoin in man in Kellaway P Petersen L eds Quantitative Analytic Studies in Ppilepsy Raven Press New York pp 115 136 1976 7 Kutt H Diphenylhydantoin Relation of plasma levels to clinical control in Woodbury D M Penry J K Schmidt K P eds Antiepileptic Drugs Raven Press New York pp 211 218 1981 8 Buchthal F Svensmark 0O Serum concentrations of diphenylhydantoin Phenytoin and phenobarbital and their relation to therapeutic and toxic effects Psychiat Neurol Neurochir 74 117 136 1971 9 Sohn R S Ferrendelli J A Inhibition of Ca transport into rat brain synaptosomes by Diphenylhydantoin DPH J Pharmacol Exp Ther 185 272 275 1973 10 Penry
16. J K Newmark M E The use of anti epileptic drugs Ann Of Intern Med 90 207 218 1979 11 Kutt H Winters W Kokenge R McDowell F Diphenylhydantoin metabolism blood levels and toxicity Arch Neurol 11 642 648 1964 12 Hyman G A Sommers S C The development of Hodgkin s disease and lymphoma during anticonvulsant therapy Blood 28 416 427 1966 13 De Vries S I Haematological aspects during treatment with anticonvulsant drugs Ppilepsia 6 1 15 1965 14 Dent C E Richens A Rowe D J F Stamp T C B Osteomalacia with longterm anticonvulsant therapy in epilepsy Brit Med J 4 69 72 1970 0120 249 977 FAX 0120 247 477 3 0 EA EA ED ED
17. 780025 006 13A2X00197218061 2008 4 6 2006 10 5 30402000 1 2 3 4 5
Download Pdf Manuals
Related Search